Trial
NCT05182476
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Neurocrine Biosciences
Collaborators
—
Condition
Schizophrenia
Intervention
Placebo
Why stopped
Failed to meet the primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-02